Prøve GULL - Gratis

Is China's Healthcare Industry Going To Gain From Covid-19 Crisis?

BioSpectrum Asia

|

May 2020

COVID-19 has shaken the world and caused enormous challenges to economies and people’s lives. China being the epicenter of the epidemic has been hit particularly hard. The COVID-19 outbreak has brought more attention to the healthcare and pharmaceutical industries. Experts believe that this outbreak will serve as a catalyst to the transformation of the sector in China. How would this public health crisis change China’s healthcare industry, which was projected to be worth $2.4 trillion by 2030? Let’s find out.

- Ayesha Siddiqui

Is China's Healthcare Industry Going To Gain From Covid-19 Crisis?

The first case of COVID-19 in China was reported in December 2019. Since then, the country has reported 83,912 cases, and 4,637 deaths, according to the data from US based John Hopkins Institute. The outbreak has brought terrible public health crisis and significant economic costs. According to the official data released, China’s Gross Domestic Product (GDP) fell 6.8 per cent in January- March year-on-year, a slightly larger decline than the 6.5 per cent forecast by analysts and reversing a 6 per cent expansion in the fourth quarter of 2019. It was the first contraction in the world’s second-largest economy since 1992. According to the International Monetary Fund (IMF), China is expected to grow by 1.2 per cent this year. In January 2020, the firm had predicted a 6 per cent growth. However, all is not lost, the country is expected to see a rebound in activity later this year, with growth bouncing back to 9.2 per cent next year, the IMF predicts. This all could have a ripple effect in the healthcare sector of the country.

Post COVID-19 Chinese Healthcare

Healthcare sector ranks eighth in China, and the epidemic has shed light on the areas which need to be improved. There’s no doubt this will have a profound impact on the several subsectors related to the industry.

Healthcare reform will speed up in the coming months, especially strengthening of the primary care system and integration with public health crisis management system. There will be further improvements on the sustainability and affordability of the social medical insurance funds.

FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Translate

Share

-
+

Change font size